Last year, Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against infection with just a single injection every six months. The drug, now under regulatory review, was greeted as a breakthrough, the closest thing the field has ever had to a vaccine.
On Tuesday, Gilead published early data suggesting a new formulation of the drug could be used to prevent infection with just a single shot every year.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in